

Confronting Lung Cancer Starts Here[®]



GO2 for Lung Cancer relentlessly confronts lung cancer on every front, every day, for everyone. Founded by patients and survivors, we are dedicated to increasing survival for those at risk, diagnosed, and living with lung cancer.

go2.org

We are relentless in our vision to live in a world without lung cancer.


OUR COMPREHENSIVE APPROACH

- Engaging and supporting people living with and at risk of lung cancer from early detection and treatment to long-term survival.
- Mobilizing patient-driven research innovation to find cures.
- Expanding GO2's Centers of Excellence (COE) network of community hospitals, clinics, academic, and Veterans Medical Centers so patients can receive care close to home.
- Increasing federal research funding and improving accessible and affordable healthcare, especially for those vulnerable and underserved.
- Heightening awareness with campaigns to fight the stigma and promote the importance of early detection and precision medicine.

Maintained highest four-star rating for the eighth consecutive year with a 100% score, as rated by Charity Navigator, placing GO2 among 10% of most effective charities in the nation.




GET THE FACTS



Lung cancers make up almost **20% of all cancer deaths**, losing more people each year than breast, prostate,

and colon cancers combined, yet receive the **least amount of federal funding** (based on National Institutes of Health (NIH) research dollars per death).



More than **14.5 MILLION AMERICANS** are living with or at risk for lung cancer, the leading cause of cancer death for men and women in every ethnic group.

234,580 Americans are estimated to be diagnosed with lung cancer this year.



34% more women die of lung cancer than breast cancer.

There is a **76% higher** incidence of lung cancer among our veterans than those who never served.



Early detection at a localized stage could result in **38% more** five-year survivors among people diagnosed this year — **that's 90,000 survivors!**

Lung cancer's five-year survival rate has stayed below 27% for 40 years. Breast, prostate, and colon cancer's five-year survival rates are now 89%, 99%, and 65%, respectively.



There is a **63% five-year survival rate** when lung cancer is detected early as compared to a 9% late-stage survival. **That's a 10x greater chance of survival, but only 4.5% of eligible people were screened last year.**



Women who are never smokers are **2X more likely** to get lung cancer as men who are never smokers.

80% of people diagnosed today are former or never smokers.

OUR GOAL

Increase the rate of lung cancers diagnosed at an early curable stage.

Our 2023 impact:

961 Centers of Excellence (COE) healthcare facilities

(including seven Veterans Medical Centers) in 45 states, plus Washington, DC, are addressing health inequities by serving as the national model of excellence for lung cancer screening and care in the community setting where 80% of Americans receive their care.

More than 50% early detection

rate within our COE screening programs compared to the 18% national average in US medical facilities.

60,000 more people

are eligible for screening after we successfully advocated for lowering the initial screening age from 55 to 50 and the smoking history requirement from 30 pack years to 20 pack with national coverage by Medicare/Medicaid.

900,000+ veterans at higher risk for lung cancer are supported by our extended formal agreement with the Department of Veterans Affairs to provide education, technical assistance, and access to care.

Launched the next phase of our **Origins Research Initiative, INHERIT**, with the Addario Lung Cancer Medical Institute (ALCMI—our medical consortium) and the Dana-Farber Cancer Institute to identify the inherited risk factors for lung cancer in families, with the goal of recruiting 1,000 people.

Established relationships with **16 faith-based organizations** in communities of color to educate their health ministries and prepare them to advocate and improve the uptake of lung cancer screening through access to G02 Centers of Excellence and mobile screening.

We put people at the center of everything we do.



OUR GOAL

Increase the rate of comprehensive biomarker testing and precision medicine.

Our 2023 impact:

Supported 800+ individuals in the last two years via **LungMATCH**, our on-demand, personalized treatment and trial navigation program. **97% of participants reported discussions** with their providers on comprehensive biomarker testing and treatment options, and **41% enrolled** in a clinical trial after working with our specially trained navigators.

14 ongoing or completed research studies from early detection to treatment and survivorship, including four innovative direct-to-patient clinical trials run by ALCMI.

11 scientific papers published covering stigma, tobacco cessation, lung cancer biology, and treatment resistance.

6 targeted programs address health inequities, including increasing diversity in clinical trials and educating and supporting high-risk communities of color and low-income, Latino/Hispanic, and Asian American communities about screening, treatment, and survivorship.

In partnership with the American Cancer Society Cancer Action Network, **secured legislation in 13 states** to provide coverage for and ensure equitable access to comprehensive biomarker testing.

29 COEs participating in active research studies with ALMCI focused on advancing more personalized care across the continuum, with over **1,000 people** enrolled to date.



29 COEs participated in active research studies.

OUR GOAL

Increase reach and impact of community engagement to yield better outcomes.

Our 2023 progress:

Reached nearly **1.4 billion people**, including 428,000+ website visitors, and recorded more than 76,000 digital marketing views.

116,700 people at risk or impacted by lung cancer received free tailored education through our Helpline (with a **95% satisfaction rate!**) and navigation and/or supportive services from our professionally trained team.

Received 43,700 views from 38 countries of our monthly Lung Cancer Living Room Expert Speaker Series.

Distributed 70,286 educational publications from our reader-friendly library of 32 brochures providing information on every aspect of the disease.

Conducted **26 community events** to raise awareness and funding with **6,300 participants and supporters**, raising **\$1.6 million** to advance our lifesaving mission.

Secured \$225 million in federal funding to date through the only annual, national lung cancer advocacy summit taking place in Washington, DC. Advocates representing **27 states attended, generating over 56,000 social media impressions** and nearly **2,000** social media engagements.

Championed **2 historic legislative efforts**, the Lung Cancer Mortality Reduction Act and the Women and Lung Cancer Research and Preventive Services Act, bringing national attention and priority funding to lung cancer's unique and devastating impact.

Secured **14 new community partnerships** for the READY-Lung project aimed at increasing lung cancer awareness, treatment, and supportive care for economically disadvantaged African Americans.

Received **2 community engagement awards** to address health disparities within the Hispanic and Latinx communities and the stigmatized lung cancer community.

Conducted the annual COE Summit, bringing together more than **190 healthcare professionals** and advocates from across the country to explore progress in lung cancer early detection and treatment to drive improved patient outcomes near home. **88% of attendees** indicated that the COE Summit exceeded their expectations.

Expanded the G02 Global Knowledge Center for lung cancer providers, reaching **49 states and 25 countries to date with nearly 900 unique learners and 1,900** course enrollments.

Conducted the annual Shine A Light on Lung Cancer Program at **235 healthcare facilities in all 50 states and 4 countries** to educate, connect, and celebrate our community while raising global awareness.

Expanded the **Lung Cancer Awareness Movement Coalition to 42 members on 6 continents** committed to bringing awareness and amplifying the global conversation around lung cancer.

OUR GOAL

Improve survivors' quality of life as our community lives longer.

Our 2023 impact:

755,000 views of our comprehensive video education library helped educate, inspire, advocate, and improve quality of life for our community.

4,031 members of our online Lung Cancer Support Community received the latest information on various aspects of surviving and thriving with the disease.

To date, **over 2,600 participants** from over 60 countries have joined our Lung Cancer Registry (available in five languages) to empower people to contribute their personal experiences to advance research, care, and quality of life. 7 presentations/publications have been delivered to date.

Established a **new survivorship designation** within the COE network to facilitate the development and implementation of survivorship care plans and resources to improve quality of life for all people living with the disease.

Conducted the inaugural Lung Cancer Navigator Workshop, with **70 navigators** using our Lung Cancer Navigator Core Curriculum to improve quality of care and life for people at risk or living with the disease.

Championed **2 legislative efforts** to increase federal support for improved palliative care and long-term survivorship needs.





go2.org